The largest database of trusted experimental protocols

3 protocols using as2444697

1

Measuring Growth Factor Shedding in Breast Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Validation of screen hits was conducted using MDA-MB-231 cells plated in
96 well plates. 90% confluent cells were stimulated with 100 nM PMA for
2 hours after which time supernatant was collected. A microsphere-based Luminex
Technology and ELISA kits (DY239, R&D Systems) were used to measure a
panel of shed growth factors, as previously described (49 (link)).
To measure changes in TGFα shedding with inhibitor treatments,
40,000 cells per well were plated in a 96 well plate, allowed to adhere
overnight and then incubated with serum-free medium for 3 hours. Cells were then
pre-treated for 1 hour with DMSO control or IRAK4 inhibitor (5uM AS2444697,
TOCRIS) or IRAK1/4 inhibitor (5 uM IRAK1/4 Inhibitor I, TOCRIS) or IKKb
inhibitor (2 uM BI605906, TOCRIS) or metalloprotease inhibitor (10uM Batimistat,
TOCRIS) after which medium was replaced with fresh media containing the
respective inhibitor and 100nM PMA (or vehicle). After 1 hour incubation,
TGFα shedding in the cell culture medium was quantified using the DuoSet
ELISA Development System (R&D systems). Cell viability was immediately
assessed using CellTiter-Glo Luminescent Cell Viability Assay (Promega).
TGFα shedding values (pg/mL) were normalized to cell viability
measurements.
+ Open protocol
+ Expand
2

Gemcitabine and IL-1β Inhibition

Check if the same lab product or an alternative is used in the 5 most similar protocols
Gemcitabine was purchased from the Siteman Cancer Center Pharmacy. Details of inhibitors were: IRAK1/4 inhibitor (Sigma, cat# I5409), AS2444697 (Tocris, cat#5430), IMD-0354 (Tocris, cat#2611), anti-mouse IL-1β neutralizing antibody (Invivogen, clone 7E3), anti-human IL-1β neutralizing antibody (Invivogen, clone 4H5).
+ Open protocol
+ Expand
3

In Vitro and In Vivo Anticancer Drug Screening

Check if the same lab product or an alternative is used in the 5 most similar protocols
All reagents and drugs were obtained from the following (Table S2): Gemcitabine and irinotecan (Washington University Siteman Cancer Center Pharmacy), 5-FU (Sigma-Aldrich #F6627), oxaliplatin (Sigma #O9512), SN-38 (Sellekchem #S4908), PF3644022 (Tocris #4279), (5Z)-7-Oxozeaenol (Tocris #3604), hydroxychloroquine (Sigma-Aldrich #H0915), recombinant TNFα (BioLegend #570104), trametinib (Selleckchem #S2673), AS2444697 (Tocris #5430), KU55933 (Selleckchem #S1092), VE821 (Selleckchem #S8007), SP600125 (Selleckchem #S1460), IMD0354 (Tocris #2611), GSK963 (Selleckchem cat# S8642). ATI-450 was provided by Aclaris Therapeutics Inc. under material transfer agreement. For in vivo experiments, ATI-450 was formulated in chow at 1000 parts per million, which achieved >60% inhibition of LPS-induced TNFα expression in mice (51 (link))
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!